Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack
of high level evidence for treatments, we seek to perform a randomized, placebo-controlled,
double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease.
Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's
disease, but there is evidence that it could be effective in helping with vertigo attacks and
other aspects of the disorder.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
American Hearing Research Foundation Cures within Reach Foundation
Treatments:
Norepinephrine Serotonin Serotonin and Noradrenaline Reuptake Inhibitors Venlafaxine Hydrochloride